Core Insights - Polyrizon Ltd. announced positive preclinical results for its hydrogel-based Trap & Target (T&T) platform, indicating effective drug delivery to the upper nasal cavity, which is crucial for central nervous system (CNS) applications [1][4] Group 1: Study Results - The study, conducted with the University of Parma, showed that Polyrizon's hydrogel formulation achieved over 60% preferential accumulation in the middle and upper turbinates, enhancing nose-to-brain transport [3] - The results suggest potential applications for CNS indications, such as opioid overdose treatment and seizure management, where rapid brain access is critical [3][4] Group 2: Technology Validation - The CEO of Polyrizon emphasized the validation of the T&T technology's ability to achieve localized deposition in favorable nasal regions, which could lead to new therapies for acute neurological and psychiatric conditions [4] - The hydrogel demonstrated consistent delivery to upper nasal segments while maintaining favorable handling characteristics, supporting further preclinical development [4] Group 3: Future Plans - Polyrizon plans to validate these preclinical results in animal models and initiate safety studies as part of its translational roadmap for the T&T technology [5]